Middle East Fertility Society Journal (Jul 2022)

GnRH agonist as a luteal support in IVF cycle: mini-review—is there a role?

  • Hasan Maghraby,
  • Amr S. Abdelbadie,
  • Ashraf Aboali,
  • Aboubakr Elnashar

DOI
https://doi.org/10.1186/s43043-022-00109-3
Journal volume & issue
Vol. 27, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background It has been established that assisted reproductive technology (ART) cycles are usually accompanied by a defective luteal phase, and that luteal phase support (LPS) is mandatory to improve reproductive outcomes. This review aims to summarize the hypothesis, safety and current evidence about GnRH agonist as a luteal phase support in ART. Main body There are many regimens of luteal phase support to improve ART outcomes in women undergoing fresh and thawed cycles. Luteal phase support drugs include progesterone, human chorionic gonadotropin, gonadotropin-releasing hormone agonist, estradiol, and recombinant luteinizing hormone. There is some debate about optimal drugs and timing for start of LPS in ART cycles. Conclusion Although most centers support luteal phase by vaginal progesterone, GnRH agonist is a debatable drug for luteal support cycles.

Keywords